This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCabe, B. J. Articles by Restifo, N. P. Search for Related Content PubMed PubMed Citation Articles by McCabe, B. J. Articles by Restifo, N. P.

Minimal Determinant Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic Antitumor Cytolytic T Lymphocyte Responses

Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892

Anticancer vaccine strategies can now target intracellular antigens that are involved in the process of malignant transformation, such as oncogene products or mutated tumor suppressor genes. Fragments of these antigens, generally 8–10 amino acids in length and complexed with MHC class I molecules, can be recognized by CD8+ T lymphocytes (T_CDs+). To explore the possibility of using a genetically encoded, minimally sized fragment of an intracellular antigen as an immunogen, we constructed a recombinant vaccinia virus encoding an 8-residue peptide derived from chicken ovalbumin that is known to associate with the mouse H-2K^b molecule. Compared to standard methods of immunization, recombinant vaccinia virus expressing the minimal determinant as well as full length ovalbumin were the only approaches that elicited specific primary lytic responses in C57BL/6 mice against E.G7OVA, a transfectant of the murine thymoma EL4 containing the ovalbumin gene. Stimulating these effectors in vitro with OVA_257–264 peptide induced H-2K^b-restricted T_CD8+ that not only lysed but also specifically secreted IFN- in response to an antigen. Furthermore, when transferred adoptively, these anti-OVA_257–264 T_CD8+ cells significantly reduced the growth of established ovalbumin-transfected tumors in a pulmonary metastasis model system. Synthetic oligonucleotides encoding minimal antigenic determinants within expression constructs may be a useful approach for treatment of neoplastic disease, thus avoiding the potential hazards of immunizing with full-length cDNAs that are potentially oncogenic.

¹ Participating in the Howard Hughes Medical Institute/NIH Research Scholar's Program, Bethesda, MD.

² To whom requests for reprints should be addressed, at Building 10, Room 2B42, National Cancer Institute, 10 Center Drive, MSC 1502, Bethesda, MD 20892-1502.

Received 11/18/94. Accepted 2/16/95.

This article has been cited by other articles:

				S. Sarma, X.-F. Bai, J.-q. Liu, K. F. May Jr., P. Zheng, and Y. Liu On the Role of Unmutated Antigens in Tumor Rejection in Mice with Unperturbed T-cell Repertoires Cancer Res., September 15, 2003; 63(18): 6051 - 6055. [Abstract] [Full Text] [PDF]

				D. R. Siemens, B. D. Elzey, D. M. Lubaroff, C. Bohlken, R. J. Jensen, A. K. Swanson, and T. L. Ratliff Cutting Edge: Restoration of the Ability to Generate CTL in Mice Immune to Adenovirus by Delivery of Virus in a Collagen-Based Matrix J. Immunol., January 15, 2001; 166(2): 731 - 735. [Abstract] [Full Text] [PDF]

				N. Maitre, J. M. Brown, M. Demcheva, J. R. Kelley, M. A. Lockett, J. Vournakis, and D. J. Cole Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination Clin. Cancer Res., May 1, 1999; 5(5): 1173 - 1182. [Abstract] [Full Text] [PDF]

				T. F. Greten and E. M. Jaffee Cancer Vaccines J. Clin. Oncol., March 1, 1999; 17(3): 1047 - 1047. [Abstract] [Full Text] [PDF]